Abstracts Archive - Page 1832 of 2425 - ACR Meeting Abstracts

Abstract Number: 2145 • 2015 ACR/ARHP Annual Meeting
Ixekizumab Improves Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Alice B. Gottlieb¹, Philip J. Mease², Raquel S. Cuchacovich^3,4, Catherine L. Shuler⁵, Chen-Yen Lin⁵, Russel T. Burge⁵, Suvajit Samanta⁵, Chin H. Lee⁵ and Dafna D. Gladman⁶, ¹Dermatology, Tufts Medical Center, Boston, MA, ²Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA, ³School of Medicine, Rheumatology Division, Indiana University, Indianapolis, IN, ⁴Bio Medicines Business Unit/Autoimmune Medical, Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease associated with psoriasis, peripheral arthritis, enthesitis, dactylitis, and spondylitis. PsA has a significant negative impact…
Abstract Number: 2146 • 2015 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis in Anti-TNF-Naive Patients and Those Previously Exposed to Anti-TNF Therapy: 52-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Dosing
Arthur Kavanaugh¹, Iain B. McInnes², Philip J. Mease³, Stephan Hall⁴, Hector Chinoy⁵, Alan J Kivitz⁶, Manmath Patekar⁷, Zailong Wang⁸ and Shephard Mpofu⁹, ¹University of California, San Diego School of Medicine, LaJolla, CA, ²Immunology, Infection and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁴Monash University, Melbourne, Australia, ⁵University of Manchester, Manchester, United Kingdom, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Novartis Healthcare Pvt. Ltd., Hyderabad, India, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: There remains an unmet need for additional treatment options for patients (pts) with psoriatic arthritis (PsA) who have had an inadequate response to or…
Abstract Number: 2147 • 2015 ACR/ARHP Annual Meeting
The Effect of Sulfasalazine and Methotrexate on the Immunogenicity of Infliximab and Adalimumab in Patients with Spondyloarthritis
Ana Martínez¹, Chamaida Plasencia-Rodriguez², Dora Pascual-Salcedo³, Eva L. Kneepkens⁴, Gertjan Wolbink⁵, Alejandro Villalba⁶, Teresa Jurado¹, Diana Peiteado⁶, Laura Nuño⁶, Andrea Jochems¹ and Alejandro Balsa⁶, ¹Immunology Unit, La Paz University Hospital-IdiPaz, MADRID, Spain, ²Rheumatology Department, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ³Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, ⁴Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁶Rheumatology, La Paz University Hospital-Rheumatology Department, Madrid, Spain
Background/Purpose: Classic DMARDs are not routinely prescribed for axial spondyloarthritis (SpA). Recent studies have found that concomitant therapy with methotrexate (MTX) reduced immunogenicity of TNF…
Abstract Number: 2148 • 2015 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in Psoriatic Arthritis: 2-Year Efficacy and Safety Results from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial
Philip J. Mease¹, Iain B. McInnes², Bruce Kirkham³, Arthur Kavanaugh⁴, Proton Rahman⁵, Désirée van der Heijde⁶, Robert B.M. Landewé⁷, P Nash⁸, Luminita Pricop⁹, Zailong Wang¹⁰ and Shephard Mpofu¹¹, ¹Rheumatology Research, Swedish Medical Center, Seattle, WA, ²Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ³Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, ⁴University of California, San Diego School of Medicine, LaJolla, CA, ⁵Medicine, Memorial University, St John's, NF, Canada, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷University of Amsterdam and Atrium Medical Center, Amsterdam, Netherlands, ⁸Department of Medicine, University of Queensland, Brisbane, Australia, ⁹Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: In the Phase 3, randomized, double-blind, placebo (PBO)-controlled, FUTURE 1 study (NCT01392326), the anti–interleukin-17A monoclonal antibody secukinumab provided rapid and significant improvements in key…
Abstract Number: 2149 • 2015 ACR/ARHP Annual Meeting
Dose Reduction Compared with Standard Dosing for Maintenance of Remission in Patients with Spondyloarthropathies and Clinical Remission with Anti-TNF: A Randomised Real-Life Trial
Jorge Gratacos-Masmitja¹, Caridad Pontes², Ferran Torres³, Xavier Juanola⁴, Antoni Vallano⁵, TC Salman-Monte⁶, Francisco J. Blanco⁷, Agusti Sellas-Fernandez⁸, Raimon Sanmarti⁹, Gonzalo Calvo¹⁰, Teresa Clavaguera¹¹, Raul Veroz Gonzalez¹², Juan Carlos Torre Alonso¹³, Jesus Sanz¹⁴, Cristina Avendaño¹⁵, Carlos Rodriguez-Lozano¹⁶, Luis Francisco Linares¹⁷, Ana Urruticoechea¹⁸, Eduardo Collantes-Estévez¹⁹, Rosa Morla Novell²⁰, Delia Reina²¹, Eduardo Cuende²², Pedro Zarco²³, Cruz Fernández- Espartero²⁴, Rosario Garcia-Vicuña²⁵, Carlos Alberto Montilla Morales²⁶, Eugenio De Miguel²⁷, Roser Vives² and Mireia Moreno²⁸, ¹Rheumatology, Hospital de Sabadell - Institut Universitari Parc Taulí, Sabadell, Spain, ²Clinical Pharmacology, Hospital de Sabadell - Institut Universitari Parc Taulí, Sabadell, Spain, ³Biostatistics and Data Management Platform, IDIBAPS - Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Rheumatology, Hospital Universitari de Bellvitge, Barcelona, Spain, ⁵Hospital de Bellvitge, Barcelona, Spain, ⁶Rheumatology, Hospital del Mar/Parc de Salut Mar, Barcelona, Spain, ⁷Osteoarticular and Aging Research Lab. Proteomics Unit - Associated Node to ProteoRed, Rheumatology Division, Proteomics Group-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, Spain, ⁸Rheumatology, Hospital Universitario Valle Hebron, Barcelona, Spain, ⁹Rheumatology Department, Hospital Clinic i Provincial, Barcelona, Spain, ¹⁰Hospital Clínic de Barcelona, Barcelona, Spain, ¹¹CapiCAT group (Nailfold Capillaroscopy group from the Catalan Society for Rheumatology)., Catalonia, Spain, ¹²Hospital de Mérida, Mérida, Spain, ¹³Perez de la Sala 33, 3oA., H. Monte Naranco, Oviedo, Spain, ¹⁴Rheumatology, Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁵Hospital Puerta de Hierro - Majadahonda, Madrid, Spain, ¹⁶Hospital Ubniversitario Dr. Negrin, Las Palmas de Gran Canaria, Spain, ¹⁷Rheumatology, Hospital Virgen de la Arrixaca, Murcia, Spain, ¹⁸Hospital Can Misses, Ibiza, Spain, ¹⁹IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain, ²⁰Rheumatology UNit., Hospital Sta Tecla, Tarragona, Spain, ²¹Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ²²University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, ²³H Fundación Alcorcón, Alcorcón, Spain, ²⁴Rheumatology, Hospital La Zarzuela, Madrid, Spain, ²⁵Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²⁶Rheumatology, Hospital Universitario de Salamanca, Salamanca, Spain, ²⁷Rheumatology, University Hospital La Paz, Madrid, Spain, ²⁸Hospital de Sabadell - Institut Universitari Parc Taulí, Sabadell, Spain
Background/Purpose: Tumour Necrosis Factor alpha inhibitors (TNFi) have proven to be effective in the treatment of with spondyloarthropaties. There is rationale to support that in…
Abstract Number: 2150 • 2015 ACR/ARHP Annual Meeting
Treatment with Abatacept Prevents Experimental Dermal Fibrosis and Induces Regression of Established Inflammation-Driven Fibrosis
Matthieu Ponsoye¹, Camelia Frantz², Nadira Ruzehaji³, Muriel Elhai⁴, Barbara Ruiz¹, Anne Cauvet¹, Yannick Allanore⁵ and Jerome Avouac⁴, ¹INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, ²Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ³INSERM U1016, Paris Descartes University, Paris, France, ⁴Rheumatology A department and INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, ⁵Paris Descartes University, Rheumatology A department, Cochin Hospital, And Eular Scleroderma Trials And Research (EUSTAR) Board, Paris, France
Background/Purpose: Early stages of systemic sclerosis (SSc) are characterized by inflammatory skin infiltrates mainly composed of activated T cells. Cytotoxic T-lymphocyte associated molecule-4 (CTLA-4) is…
Abstract Number: 2151 • 2015 ACR/ARHP Annual Meeting
Inhibition of Myeloid-Associated Gene Expression in Skin Biopsy Samples of Systemic Sclerosis Patients Treated with Tocilizumab
Thierry Sornasse¹, Haiyin Chen¹, Lisa Rice², Giuseppina Stifano², Angelika Jahreis¹, Jeffrey Siegel¹ and Robert Lafyatis², ¹Genentech, South San Francisco, CA, ²Boston University School of Medicine, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is a progressive, debilitating disease with limited treatment options. IL-6 has been implicated in disease pathogenesis. Tocilizumab (TCZ), an IL-6Rα inhibitor,…
Abstract Number: 2152 • 2015 ACR/ARHP Annual Meeting
Long Noncoding H19X Is a Key Mediator of Tgf-Beta Induced Pro-Fibrotic Effects in the Pathogenesis of Systemic Sclerosis and Other Fibrotic Diseases
Elena Pachera¹, Shervin Assassi², Gloria Salazar², Mojca Frank Bertoncelj³, Rucsandra Dobrota⁴, Matthias Brock⁵, Serena Vettori⁶, Claus Hellerbrand⁷, Carol A. Feghali-Bostwick⁸, Jeorg HW Distler⁹, Gabriela Kania¹⁰ and Oliver Distler¹¹, ¹Research of Systemic Autoimmune Diseases, Division of Rheumatology, University Hospital Zurich, Schileren, Switzerland, ²Rheumatology, University of Texas Medical School at Houston, Houston, TX, ³Center of Experimental Rheumatology, University Hospital Zurich, University Zurich, Zurich, Switzerland, ⁴Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁵Department of Pulmonology, University Hospital Zurich, Schileren, Switzerland, ⁶Department of Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, ⁷Department of Internal Medicine I, University of Regensburg, Regensburg, Germany, ⁸Medicine, University of Pittsburgh, Pittsburgh, PA, ⁹Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ¹⁰Research of Systemic Autoimmune Diseases, Division of Rheumatology, University Hospital Zurich, 8952 Schlieren, Switzerland, ¹¹Division of Rheumatology, University Hospital And Eular Scleroderma Trials And Research (EUSTAR) Board, Zurich, Switzerland
Background/Purpose: Long noncoding RNAs (LncRNAs) are emerging as a novel class of noncoding transcripts involved in the regulation of gene expression. So far, for only…
Abstract Number: 2153 • 2015 ACR/ARHP Annual Meeting
Nintedanib Ameliorates Fibrotic and Vascular Manifestations in Preclinical Models of Systemic Sclerosis
Jingang Huang¹, Christian Beyer¹, Yun Zhang¹, Katrin Palumbo-Zerr², Clara Dees¹, Oliver Distler³, Georg A. Schett⁴, Stefan Lutz Wollin⁵ and Jorg HW. Distler¹, ¹Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3 and Institute for Clinical Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Department of Rheumatology, Research of Systemic Autoimmune Diseases, University Hospital Zurich, Zurich, Switzerland, ⁴Institute for Clinical Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Boehringer-Ingelheim Pharma, Div. Research Germany, Bad Biberach, Germany
Background/Purpose: Nintedanib is a tyrosine kinase inhibitor that inhibits PDGF-, FGFR-, VEGFR-receptors and Src kinases. Nintedanib has recently been approved for the treatment of idiopathic…
Abstract Number: 2154 • 2015 ACR/ARHP Annual Meeting
Inhibition of Gli Ameliorates the Pro-Fibrotic Effects of Transforming Growth Factor-Î² in Systemic Sclerosis
Ruifang Liang¹, Clara Dees², Katrin Palumbo-Zerr³, Yun Zhang³, Oliver Distler⁴, Georg Schett³ and Jeorg HW Distler³, ¹Rheumatology and Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ³Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Division of Rheumatology, University Hospital And Eular Scleroderma Trials And Research (EUSTAR) Board, Zurich, Switzerland
Background/Purpose: Hedgehog signaling plays a critical role in the pathogenesis of fibrosis in Systemic sclerosis (SSc). Besides canonical hedgehog signaling with Smoothened (Smo)-dependent activation of…
Abstract Number: 2155 • 2015 ACR/ARHP Annual Meeting
Inhibition of Sphingosine-1-Phosphate Signaling By AB22 As a Novel Strategy in the Treatment of Pulmonary Fibrosis Associated with Scleroderma
Ilia Atanelishvili¹, Yuichiro Shirai², Tanjina Akter³, Erik Stolarzewicz⁴, Rolf E Swenson⁵, Richard Silver⁶ and Galina S. Bogatkevich⁷, ¹Division of Rheumatology & Immunology, Medical University of South Carolina,Charleston,USA, Charleston, SC, ²Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ³Medical University of South Carolina, charleston, SC, ⁴Chem-Master International Inc, Stony Brook, NY, ⁵Arroyo BioSciences, Silver Spring, MD, ⁶Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ⁷Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Activation of sphingosine-1-phosphate (S1P) signaling has been extensively documented in various fibrotic conditions including pulmonary fibrosis. The aim of this study was to provide…
Abstract Number: 2156 • 2015 ACR/ARHP Annual Meeting
Damage Assessment in Giant Cell Arteritis
Tanaz A. Kermani¹, Antoine G. Sreih², David Cuthbertson³, Simon Carette⁴, Gary S. Hoffman⁵, Nader A. Khalidi⁶, Curry L. Koening⁷, Carol A. Langford⁵, Carol A. McAlear⁸, Paul A. Monach⁹, Larry W. Moreland¹⁰, Christian Pagnoux⁴, Philip Seo¹¹, Kenneth J. Warrington¹², Steven R. Ytterberg¹² and Peter A. Merkel¹³, ¹Rheumatology, University of California Los Angeles, Santa Monica, CA, ²Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, Cleveland Clinic, Cleveland, OH, ⁶McMaster University, Hamilton, ON, Canada, ⁷Rheumatology, University of Utah, Salt Lake City, UT, ⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹²Rheumatology, Mayo Clinic, Rochester, MN, ¹³Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: This study aimed to 1) catalogue damage in a longitudinal cohort of patients with giant cell arteritis (GCA) and 2) evaluate predictors of…
Abstract Number: 2157 • 2015 ACR/ARHP Annual Meeting
Relapse Characteristics and Glucocorticoid Use in Patients with Biopsy-Proven Giant Cell Arteritis
Matthew J. Koster¹, Cristian Labarca², Cynthia S. Crowson³, Ashima Makol¹, Steven R. Ytterberg⁴, Eric L. Matteson¹ and Kenneth J. Warrington¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Rheumatology Division, Mayo Clinic, Rochester, MN
Background/Purpose: Relapses in patients with giant cell arteritis (GCA) are common and often lead to higher cumulative use of glucocorticoids. This study aims to evaluate…
Abstract Number: 2158 • 2015 ACR/ARHP Annual Meeting
Mortality Associated with Giant Cell Arteritis from 1980 to 2011: An Analysis of the French National Death Certificate Database
Achille Aouba¹, Solange Gonzalez-Chiappe², Mireille Eb³, Claire Delmas¹, Grégoire Rey³, Alfred Mahr² and Boris Bienvenu¹, ¹Internal Medicine, Hospital Caen, Caen, France, ²Internal Medicine, Hospital Saint-Louis, Paris, France, ³Inserm-CépiDc, Hospital Bicêtre, Le Kremlin-Bicêtre, France
Background/Purpose: Data from mostly small cohorts consistently suggest that a diagnosis of giant cell arteritis (GCA) does not substantially affect survival but GCA- and GCA…
Abstract Number: 2159 • 2015 ACR/ARHP Annual Meeting
Second Temporal Artery Biopsies in Patients with Temporal Arteritis (TA)
John Fritzlen¹, Brian Younge², Cornelia M. Weyand³, Gene G. Hunder⁴, Jorg Goronzy⁵, Kenneth J. Warrington⁴ and Joseph Maleszewski¹, ¹Anatomical Pathology, Mayo Clinic, Rochester, MN, ²Ophthalmology, Mayo Clinic, Rochester, MN, ³Stanford, Stanford, CA, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Emory University School of Medicine, Lowance Center for Human Immunology and Rheumatology, Atlanta, GA
Background/Purpose: While many manifestations of TA improve quickly after starting glucocorticoid therapy, vascular inflammation appears to persist. To obtain more information about the duration of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].